Research progress of Hemoporfin - Part one: Preclinical study
Research progress of Hemoporfin - Part one: Preclinical study
复制标题
DOI：
10.1016/j.pdpdt.2011.09.004
复制
发表时间：
2012-06-01
影响因子：
3.3
通讯作者：
Yu, Zhengwei
中科院分区：
文献类型：
--
作者：
Pu, Yu;Chen, Wenhui;Yu, Zhengwei
第二代光敏剂Hemoporfin(7(12)-（1-甲氧基乙基）- 12（7)-（1-羟乙基）-3,8,13,17-四甲基- 21h， 23h -卟啉-2,18-二丙酸）是一种结构稳定、单线态产氧量高、光活性高、暗毒性低、清除率快的卟啉衍生物。血卟啉（Hemoporfin），又称血卟啉单甲基醚（HMME），自1989年开始在国内研究并应用于光动力治疗（PDT）。本系列报道将概述该PDT光敏剂的临床前和临床研究。本系列的第一部分将重点介绍该化合物的光学特性、活性机制、药理学和毒理学特性的临床前研究结果。(C) 2011 Elsevier B.V.版权所有
The second generation photosensitizer Hemoporfin (7(12)-(1-methoxyethyl) -12(7)-(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H,23H-porphin-2,18-dipropionic acid) is a porphyrin derivative which processes a stable structure, high singlet oxygen yield, high photoactivity, low dark toxicity and fast clearance rate. Hemoporfin, also known as hematoporphyrin monomethyl ether (HMME) has been studied and used in photodynamic therapy (PDT) in China since 1989. This series of reports will provide an overview on the preclinical and clinical studies of this PDT photosensitizer. The first part of this series will highlight the results of preclinical studies that focused on the compound's optical characteristics, mechanism of the activities, pharmacological and toxicological properties. (C) 2011 Elsevier B.V. All rights reserved.